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AIMS
Patients receiving darunavir are advised to take it concomitantly with food. The objectives of the present cross-sectional study
were to evaluate the actual concomitant food intake of patients visiting an HIV outpatient clinic.
METHODS
Sixty participants treated with darunavir/ritonavir once daily were subjected to a food recall questionnaire concerning their last
concomitant food intake with darunavir. Darunavir trough concentrations were calculated.
RESULTS
The median food intake was 507 (0–2707) kcal; protein intake, 20 (0–221)g; carbohydrate intake, 62 (0–267)g; fat intake: 14
(0–143)g; and dietary ﬁbre: 4 (0–30)g. Twenty-ﬁve patients (42%) ingested their drug with between-meal snacks. No relationship
was found between food intake and trough concentrations.
CONCLUSIONS
Clear advice on the optimal caloric intake is needed, to avoid high caloric intake in patients who already have an increased risk of
cardiovascular disease due to their HIV infection.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• In healthy volunteers, administration of 400 mg darunavir in a fasting state has been shown to result in a peak plasma
concentration and area under the curve decrease of approximately 30% compared with administration after a standard
meal.
• No signiﬁcant differences have been observed in darunavir plasma concentrations between the different diets tested.
• The advice on concomitant food intake in patient brochures varies highly in caloric intake.
WHAT THIS STUDY ADDS
• Concomitant food intake in a real-life outpatient setting varied greatly and was often unnecessarily high.
• A large number of people using darunavir take their drug with a between-meal snack.
• Healthcare providers and patient brochures should ensure that their advice on concomitant food intake does not contrib-
ute to an unhealthy diet.
Introduction
Darunavir (DRV) is a protease inhibitor (PI) that is adminis-
tered with low-dose ritonavir (RTV) to provide a pharmaco-
kinetic boost by inhibiting drug metabolism, thereby
enhancing plasma concentrations over time [1]. Although
DRV is considered to be a safe and efﬁcacious drug, a consid-
erable pharmacokinetic variability has been observed [2].
The observed variability may be partly explained by a
food effect. In a prior study assessing the food effect on the
bioavailability of DRV 400 mg (with RTV) in healthy volun-
teers, the bioavailability increased by 30% with food intake
compared with the fasting state, and no signiﬁcant differ-
ences were observed between the different diets tested [3].
Partly because of this food effect study, patients using
DRV are advised to ingest their drug concomitantly with
food. However, there is no clear-cut advice on how much
nutritional content (e.g. number of calories, and amount of
fat, protein and carbohydrate) a meal should contain. The pa-
tient product brochures seem to focus more on caloric intake
than on a healthy diet, as meals with a high caloric value are
often recommended [4–6]. As earlier studies were conducted
in controlled settings, little attention was paid to the clinical
implications in a real-life outpatient setting. The primary
objective of the present study was to determine how people
living with HIV, using once-daily DRV/RTV cope with the
concomitant food intake advice given by their care givers
and patient product brochures. Same-day DRV trough
concentrations (Ctrough) were measured and compared with
cut-off values used in clinical care.
Methods
Study design and participants
In the HIV outpatient clinic of the University Medical Center
Groningen (UMCG), patients with an appointment between
23 April 2014 and 28 July 2014 were asked to participate if
they were using DRV/RTV 800/100 mg once daily.
Consenting participants were subjected to a validated and
structured food recall questionnaire, ﬁlled in by a trained re-
searcher (A.D.) to record participants’ food intake (±30 min)
with the last DRV administration before their appointment
and the time of DRV ingestion. After performing diagnostic
tests for standard care, residual blood was analysed to
determine the DRV plasma concentration. The blood was
drawn from the patient on the same day that the food intake
questionnaire was obtained. Data concerning patient charac-
teristics, blood chemistry (e.g. renal and hepatic function)
and disease-speciﬁc results (CD4+ cell count and viral load)
were extracted from the medical records. We aimed to enrol
60 patients within the study period, as this sample size was
estimated to provide a representative overview of the con-
comitant food intake. Written informed consent was
obtained from all participants prior to any study procedure.
The ethical review board of the UMCG reviewed the study
and concluded that it was in accordance with Dutch law
(METc 2014.115).
Nutritional assessment
The validated food recall questionnaire consisted of the time
of food intake, food preparation and an accurate description
of the food and drink consumed. To assess the food quantity,
the researcher used household measures and photographic
tools, using the double-check method on products such as
milk, sugar and spices that are known to be under-reported
in such questionnaires. The Dutch National Food Consump-
tion Survey 2012–2016 was used as a reference, in addition
to the questionnaire used, to determine the type of meal
(breakfast, lunch or dinner, or a between-meal snack [7].
The food recall questionnaire was analysed by D.D. using
EvryDietist, 6.2.9.9 (Nevo 2011 data, Evry bv, Alphen aan
den Rijn, Netherlands). The following nutritional values were
calculated: energy (kcal), protein (g), carbohydrate (g), total
fat (g) and dietary ﬁbre (g). During the second half of the
study, four questions were added to the food recall question-
naire in order to optimize the interpretation of the food
intake. The ﬁrst three additional questions asked were:
1. Did your care providers advise you to eat concomitantly
with DRV?
2. If yes, what food intake did your care providers advise?
3. What amount of food do you consider appropriate for
intake concomitantly with DRV?
In the fourth question, we asked if patients changed their
food pattern as a consequence of DRV and its concomitant
food intake advice. We disregarded this question; interpreta-
tion of the answer was not possible without information on
the antiretroviral therapy taken before the start of the DRV
administration.
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Pharmacokinetic assessment
Participants were asked at which time point DRV was
ingested. The time of blood sampling was recorded. The con-
centrations of DRV in human plasma were analysed using a
validated liquid chromatography–tandemmass spectrometry
(LC–MS/MS) method. All analyses were performed on a
Thermo Fisher Scientiﬁc Inc. (San Jose, CA, USA) triple
quadrupole LC–MS/MS with a FinniganTM Surveyor® LC
pump and a FinniganTM Surveyor® autosampler. The mobile
phase consisted of an aqueous buffer (containing ammonium
acetate 5 g l–1, acetic acid 35 ml l–1 and triﬂuoroacetic
anhydride 2 ml l–1 water), water and acetonitrile and had a
ﬂow rate of 0.3 ml min–1. The calibration curves were linear
within the concentration range 0.335–33.5 mg l–1 for DRV
and had a correlation coefﬁcient (R2) of 0.999. The lower
limit of quantiﬁcation (LLOQ) for DRV was 0.27 mg l–1. This
method is precise and accurate: within-day precision ranged
between 2.2% and 3.2% for DRV, and between-day precision
from 3.0% to 5.2%. The calculated accuracy ranged from
0.0% to 11.8%.
The DRV Ctrough was deﬁned as the plasma concentra-
tion at 24 h after intake of the dose. To estimate the
Ctrough, we used a DRV iterative two-stage Bayesian popu-
lation pharmacokinetic model using the software package
MWPharm Research version 3.82 (Mediware, Groningen,
the Netherlands) [8]. The model for DRV is a one-
compartment model with input and elimination from
the central compartment. Parameters for this model are:
a volume of distribution of the central compartment of
2 l kg–1 [standard deviation (SD) 0.5 l kg–1], total body
clearance of 6.3 l h–1 1.85 m–2 (SD 1.57 l h–1 1.85 m–2),
ﬁrst-order absorption constant of 1 h–1 (SD 0.25 h–1)
and a bioavailability of 0.8 (in combination with RTV).
This model was built in-house and derived from data pro-
vided in the literature [9]. A median population pharma-
cokinetic curve was used as a cut-off value for follow-up
as in standard care [10, 11]. A DRV Ctrough below
1.07 mg l–1 is an indication for follow-up, in accordance
with the treatment protocol. The median population
pharmacokinetic curve is seen as a cut-off value for the
once-daily dosage and not as the minimally effective
concentration.
Further, the medical records of all participants were stud-
ied for medication potentially inﬂuencing the DRV
concentrations.
Statistical analysis and data processing
Ctrough levels vs. the calculated kcal, carbohydrate, protein,
total fat and dietary ﬁbre values were presented in a scatter
plot. Curve estimation tests were performed to ﬁnd the best
ﬁt. All descriptive analyses were performed using SPSS for
Windows, version 22.0 (IBM SPSS, Chicago, IL, USA).
Nomenclature of targets and ligands
Key ligands in this article are hyperlinked to corresponding
entries in http://www.guidetopharmacology.org, the com-




Sixty patients were enrolled, of whom 50 were male. Partici-
pant demographic characteristics are presented in Table 1.
Forty-seven per cent of the participants were overweight
[body mass index (BMI) ≥25 kg m–2], of whom 13% were
classiﬁed as obese (BMI ≥30 kg m–2).
Nutritional analysis
The medians of the calculated nutritional values for the meal
concomitantly ingested with DRV are shown in Table 2.
Eleven participants ingested DRV with breakfast, even with
lunch, 14 with dinner and three without concomitant food,
and 25 participants took their DRV with a between-meal
snack.
Twenty-eight (85%) of the participants interviewed about
the advice received at start of the treatment conﬁrmed that
the care provider advised them to eat concomitantly with
the ingestion of DRV. Twenty-four participants (73%)
indicated that they did not know the amount of food intake
recommended with DRV ingestion.
Pharmacokinetic analysis
The median (interquartile range) DRV Ctrough for the 60 par-
ticipants was 2.3 (1.51–3.67) mg l–1. Seven participants
(12%) had a DRV Ctrough below the used cut-off value of
1.07 mg l–1. No pattern could be detected in the DRV Ctrough
and the caloric intake. A biologically expected S-curve did
not ﬁt the data (P = 0.260), as presented in Figure 1. A linear
model ﬁtted slightly better compared with the other curve es-
timations but still showed no correlation (rho = 0.178, P =
0.173). Similar results were found for the other nutritional
values (protein, carbohydrate, total fat and dietary ﬁbre; not
Table 1
Baseline demographic characteristics of the 60 study participants
Characteristics Value (range)
Mean age (years) 45 (20–66)
Median body mass index
(kg m–2)
24.66 (16.80–39.18)





Median ASAT 29 (18–261)
Median ALAT 23 (10–784)
Mean CD4+ cell count 510 (130–1200)
Viral load (n = 44) Undetectable






ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase
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shown). The medical records of the participants did not show
use of medication interacting with DRV/RTV.
Discussion
To the best of our knowledge, this was the ﬁrst study to eval-
uate the concomitant food intake in people using the once-
daily DRV dosage in a real-life setting. Our ﬁndings showed
that people using DRV often have a unnecessarily high calo-
ric intake and that a large number of the patients take DRV
with high caloric between-meal snacks.
Patients using DRV are advised to ingest their drug con-
comitantly with food, although detailed advice on the type
of food and number of calories is not given. This is reﬂected
in the current study as the concomitant food intake among
participants varied greatly and no relationship was found
with DRV Ctrough. The high BMI (>25 kg m
–2) of participants
in the present study may partly be a consequence of the
between-meal snacks and subsequent high caloric intake.
The use of antiretroviral therapy has been associated with a
higher risk of cardiovascular and metabolic disorders, such
as hyperlipidaemia, insulin resistance, metabolic syndrome
and diabetes [13–16]. Therefore, it is important to ensure that
the advice on concomitant food intake while using DRV does
not lead to an unnecessarily higher caloric intake. Based on
the ﬁndings by Sekar et al. [3] and our ﬁndings, we suggest
that much of the food advice shown in the DRV patient bro-
chures can be adapted to healthier dietary advice [4, 5].
Due to the observational nature of the study, it is possi-
ble that a recall bias on food intake was introduced, despite
taking a careful history using a validated food recall ques-
tionnaire. Furthermore, the Ctrough was estimated using
one blood sample, which could have given a distorted view.
However, repeated blood samples would alter the actual
(cross-sectional) study design, and the use of Bayesian esti-
mation in combination with patient characteristics, dosage
and time of ingestion is a widely accepted method in daily
practice to interpret drug level results [8, 17]. Despite po-
tential weaknesses, the results of the present study provide
a good insight into the daily concomitant food intake in
patients.
A controlled food effect study in patients is needed to op-
timize recommendations on the minimal amount of con-
comitant food intake to prevent unnecessary high-caloric
and high-fat food intake in a patient group with already in-
creased risks for cardiovascular and metabolic diseases.
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